IRulya Therapeutics

IRLA on Nasdaq. Market value $432m.

Watch this stockFree. We tell you when something changes.

Price checks use the past 12 months to September 2026. Quality checks use five annual reports, the latest for the year to December 2025.

Should I look at this?

Not a fit for our list right now

See Health care stocks that passed both tests

This is not advice. Check the numbers below.

Compare with another stock

Cash yield
past 12 months to September 2026
-10.8%low

For every $100 of what the whole company costs, it produced $-10.85 of spare cash in the past 12 months. A savings account pays about $4.

Price to profit
past 12 months to September 2026
n/a

The filings do not give us enough to work this out.

Return on capital
five annual reports to December 2025
-73.4%five-year median

Each dollar kept in the business earns -73 cents a year. Above 10 is good.

Quality score: 20 of 100. Price score: 0 of 100. Our list needs 70 on quality and 60 on price.

$39.88 a share, 164% above its 1-year low

Over the past year the price has ranged from $15.10 to $910.00.

Pays no dividend

Prices from Friday’s close (20 November).

Five years of cash, in billions

-0.1
-0.0
-0.0
-0.0
-0.0
-0.0
2021202220232024202512 monthsto Sep '26
Revenue
n/an/an/an/an/a
Operating margin
n/an/an/an/an/a
Debt to equity
n/a0.000.160.48n/a
Shares outstanding
0.04bn0.04bn0.04bn0.06bn0.01bn

Health checks

  • Free cash flow positive0 of 5 years
  • Accounting looks honest (Beneish)Not enough data
  • Financial strength (Piotroski)Not enough data
  • Profit backed by cash (accruals)No
  • DebtUnknown
  • Revenue growth, five yearsUnknown
  • Buying back its own sharesYes, 70% fewer since 2021

The quarter to September 2026

How the business did, compared with the same quarter a year earlier.

  • A loss of $28 million, compared with a loss of $13 million a year ago.
  • Over the past 12 months it spent $47 million more cash than it brought in, compared with $39 million a year earlier.
  • 4350% more shares than a year ago. Each share owns a bit less of the company.
Profit by quarter
Profit by quarter
Quarter toAmount
December 2024-$12m
March 2025-$15m
June 2025-$16m
September 2025-$13m
December 2025-$39m
March 2026$36m
June 2026-$75m
September 2026-$28m

From the company's quarterly reports to the SEC.

Dates

Next results (estimated)
n/a
Last annual report (10-K)
10 April 2026
Next quarterly (estimated, 10-Q)
12 February 2027

Who owns it

We don't have fund holdings for this stock yet.

Big holders and activists

9 investors own more than 5%.

  • GROUP ONE TRADING LLC
    Passive investor
    10.7%
    Since 28 February 2026
  • at least 10.0%0.0 pts
    (filed with 4 related holders)
    Since 30 September 2026
  • at least 10.0%
    (filed with 1 related holder)
    Since 30 June 2026
  • at least 8.8%+3.2 pts
    (filed with 3 related holders)
    Since 30 September 2026
  • Perceptive Advisors LLC
    Passive investor
    at least 8.4%
    (filed with 2 related holders)
    Since 6 October 2026
  • at least 7.9%0.0 pts
    (filed with 1 related holder)
    Since 9 October 2026
  • Integrated Core Strategies (US) LLC
    Passive investor
    at least 7.2%
    (filed with 3 related holders)
    Since 4 June 2026
  • James B. Tananbaum
    Passive investor
    at least 6.0%
    (filed with 4 related holders)
    Since 6 October 2026
  • Sofinnova Capital VIII
    Passive investor
    at least 2.7%−2.7 pts
    (filed with 7 related holders)
    Since 31 March 2025
  • Ikarian Capital, LLC
    Passive investor
    Sold down below 5%
    Since 30 September 2026
  • Sold down below 5%
    Since 30 June 2026
  • Genextra S.p.A.
    Passive investor
    Sold down below 5%
    Since 7 July 2025

From Schedule 13D and 13G filings: anyone owning more than 5% must file one.

What insiders did

No insider bought shares on the open market in the last 12 months. 1 sold $173,500.

  • Benatti Luca
    Director
    Sold
    Date
    26 December 2025
    Shares
    50,000
    Price
    $3.47
    Value
    $173,500

From Form 4 filings: insiders must report trades in their own company's shares within two days.

What could go wrong

  • It owes more than it owns on paper (negative equity). Often that's from borrowing to buy back shares.

Whether the price already reflects the risks is what the deep dive is for.

The deep dive

Everything above is arithmetic on public filings. The deep dive reads the last ten years of annual reports, the proxy statements, and the earnings calls, then argues the case the way Buffett, Klarman, and Hohn would, and checks every claim against the source.

  • What the business is worth, as a range, and the margin of safety at today’s price
  • Prices to start buying, buy, and buy hard
  • The three things that would make this a mistake
  • Every number footnoted to the filing it came from
Create a free account to run it

Your first deep dive is free.

What a finished deep dive looks like

Not advice. Numbers on this page come from SEC filings and are updated each night; prices are updated again after the US market closes. The five-year figures are rounded.